Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?
Reads0
Chats0
TLDR
In this article, a review briefly describes recent advances in the targeted therapies for primary sjogren's syndrome (pSS) treatment mainly include B cell-depleting agents, inhibitors of B cell activation, and agents that target co-signaling molecules or proinflammatory cytokines.Abstract:
Primary Sjogren's syndrome (pSS) is an autoimmune exocrinopathy characterized by dryness symptoms. This review briefly describes recent advances in the targeted therapies for pSS. Biologics evaluated for pSS treatment mainly include B cell-depleting agents, inhibitors of B cell activation, and agents that target co-signaling molecules or proinflammatory cytokines. Small molecule inhibitors that target signaling pathways have also been evaluated. However, current evidence for the efficacy of targeted therapies in pSS is still sparse. Although ianalumab (an anti-B cell-activating factor [BAFF]-receptor antibody) and iscalimab (an anti-CD40 antibody) are promising biologics for pSS, their efficacy still needs to be evaluated in larger clinical trials. For other biologics, clinical trials have found no differences versus placebo in the change from baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) score and fatigue score. Possible causes of the disappointing outcomes mainly include the inefficacy of those evaluated biologics in treating pSS, the high heterogeneous nature of pSS, irreversible exocrine glandular failure at advanced disease stages, inappropriate recruitment strategy in clinical trials, and outcome measures. Early diagnosis and glandular function-centered outcome measures may help to improve the current situation in the systemic therapy of pSS.read more
Citations
More filters
Journal ArticleDOI
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)
Jacques-Eric Gottenberg,A. Chaudier,Yves Allenbach,Arsène Mekinian,Zahir Amoura,Patrice Cacoub,Divi Cornec,Eric Hachulla,Pierre Quartier,Isabelle Melki,Christophe Richez,Raphaèle Seror,Benjamin Terrier,Valérie Devauchelle-Pensec,Julien Henry,Marc Gatfosse,Laurence Bouillet,Emeline Gaigneux,Vincent André,G. Baulier,A Saunier,Marie-Jeanne Desmurs,Antoine Poulet,Mathieu Ete,Boris Bienvenu,Marie-Elise Truchetet,Martin Michaud,Claire Larroche,Azeddine Dellal,Amélie Leurs,S. Ottaviano,H. Nielly,Guillaume Vial,Roland Jaussaud,Bénédicte Rouvière,Pierre-Yves Jeandel,Aurélien Guffroy,Anne-Sophie Korganow,Mathieu Jouvray,Alain Meyer,Emmanuel Chatelus,Christelle Sordet,Renaud Felten,Jean Sibilia,Samira Litim-Ahmed-Yahia,J.F. Kleinmann,Xavier Mariette +46 more
TL;DR: The TATA registry as mentioned in this paper is a prospective, observational, national and independent cohort follow-up study of patients with refractory low-prevalence autoimmune and inflammatory systemic diseases.
Journal ArticleDOI
Suppression of Autoimmune Rheumatoid Arthritis with Hybrid Nanoparticles That Induce B and T Cell Tolerance to Self-Antigen.
Katarzyna Brzezicka,Britni M. Arlian,Sheng-hong Wang,Merissa Olmer,Martin Lotz,James C. Paulson +5 more
TL;DR: In this article , a lipid monolayer encapsulating a PLGA core loaded with rapamycin was used to induce tolerance in both T cells and B cells to a self-antigen.
Journal ArticleDOI
Diagnostic markers and potential therapeutic agents for Sjögren’s syndrome screened through multiple machine learning and molecular docking
Liqing Zhou,Haiyan Wang,He Zhang,Fei Wang,Wenjing Wang,Haitao Zhou,Shiyong Xin,Jian-Guo Zhang,Xiaofei Shi +8 more
TL;DR: Wang et al. as discussed by the authors used support vector machine, least absolute shrinkage and selection operator regression, random forest, and weighted correlation network analysis to find diagnostic markers and effective therapeutic ways for primary Sjögren's syndrome.
Journal ArticleDOI
Loss of <scp>ATG5</scp> in <scp>KRT14</scp> <sup>+</sup> cells leads to accumulated functional impairments of salivary glands via pyroptosis
Qiuhui Li,Uğur DEMİRBAĞ +1 more
TL;DR: In this article , the role of ATG5 in salivary gland (SG) diseases such as xerostomia, which has a serious impact on quality of life was investigated.
Journal ArticleDOI
Screening biomarkers for Sjogren’s Syndrome by computer analysis and evaluating the expression correlations with the levels of immune cells
Yafang Zhong,Wei Zhang,Dongzhou Liu,Zhipeng Zeng,Sheng-bin Liao,Wanxia Cai,Jiayi Liu,Lian Li,Xiaoping Hong,Donge Tang,Yong Dai +10 more
TL;DR: Wang et al. as discussed by the authors used machine learning algorithm to mine possible diagnostic biomarkers for Sjögren's syndrome (SS) patients and assessed the biomarkers' diagnostic value using the receiver operating characteristic (ROC) curve.
References
More filters
Journal ArticleDOI
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie,Michelle A. Petri,Omid Zamani,Ricard Cervera,Daniel J. Wallace,D. Tegzova,Jorge Sanchez-Guerrero,Andreas Schwarting,Joan T. Merrill,W. Winn Chatham,William Stohl,Ellen M. Ginzler,Douglas R. Hough,Z. John Zhong,William W. Freimuth,Ronald F van Vollenhoven +15 more
TL;DR: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Journal ArticleDOI
Molecular mechanism and function of CD40/CD40L engagement in the immune system.
TL;DR: The essential role CD40 plays in adaptive immunity is underscored and a wide spectrum of molecular and cellular processes is regulated by CD40 engagement including the initiation and progression of cellular and humoral adaptive immunity.
Journal ArticleDOI
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome A consensus and data-driven methodology involving three international patient cohorts
Caroline H. Shiboski,Stephen Shiboski,Raphaèle Seror,Lindsey A. Criswell,M. Labetoulle,Thomas M. Lietman,Astrid Rasmussen,Hal Scofield,Claudio Vitali,Simon J Bowman,Xavier Mariette +10 more
TL;DR: A single set of data-driven consensus classification criteria for primary Sjögren's syndrome performed well in validation analyses and are well suited as criteria for enrolment in clinical trials.
Journal ArticleDOI
EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome
Raphaèle Seror,Philippe Ravaud,Simon J Bowman,Gabriel Baron,Athanasios G. Tzioufas,Elke Theander,Jacques-Eric Gottenberg,Hendrika Bootsma,Xavier Mariette,Claudio Vitali +9 more
TL;DR: The ESSDAI is a clinical index designed to measure disease activity in patients with primary Sjögren's syndrome and should facilitate clinical research and be helpful as an outcome measure in clinical trials.
Journal ArticleDOI
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome
TL;DR: BLyS may play a part in activating specific autoreactive B cells and modulating the level of production of autoantibodies which are the hallmark of the disease, and raise the possibility of a novel therapeutic approach in human SS.